Advanced Therapies – Opportunities and Challenges

Registration

Introduction by Conference Host, Seigo Izumo, Senior Vice President for Regenerative Medicine, Takeda Pharmaceuticals

Opening Keynote Session:  “The Future of Advanced Therapies”

Key Topics:
– Vision for Advanced Therapies
– How are ATMP technologies advancing in Europe generally, and the UK specifically?

• Keynote Speaker: Peter Goodfellow, Scientific Advisor, Abingworth
  • “Regenerating the Future, Again”
• Lord James O’Shaughnessy, Parliamentary Under Secretary of State for Health (Lords), UK Government
  • tbc
• Ian Campbell, Director for Health and Life Sciences, Innovate UK
  • “Innovate UK Supporting Research Development & Manufacturing in Advanced Therapies”
• Christian K. Schneider, Director of National Institute for Biological Standards and Control (NIBSC)
  • “Advanced Therapies – regulatory challenges”

Building Effective R&D Partnerships to Accelerate ATMPs

Key Topics:
– How have each of your organisations used partnerships to create effective R&D platforms
– What are you doing to accelerate the development ATMPs in partnership with other firms?
– What changes could Europe make to support effective R&D partnerships?

• Seigo Izumo, Senior Vice President for Regenerative Medicine, Takeda Pharmaceuticals
• Eduardo Bravo, Chief Executive Officer, TiGenix; EBE President
• Qasim Rafiq, Senior Lecturer (Associate Professor) in Bioprocessing of Regenerative, Cellular and Gene Therapies, UCL
• Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult
• Richard Barker, Founding Director, Centre for the Advancement of Sustainable Medical Innovation (CASMI) (moderator)

ATMPs as Cures – The Opportunities and Challenges for Europe

Key Topics:
– Emerging regenerative medicines will likely cure serious illness, but often these will be one-time treatments. How do we manage this paradigm shift in the EU to support R&D and better health?
– How are each of you focused on developing treatments, how does this R&D differ from traditional small molecule R&D?
– How can small biotech work with larger companies to foster the development of Regenerative Medicines and de-risk the inevitable disruption created highly effective, but one time treatment cures?

• Michaël Hocquemiller, Scientific Director, Lysogene
  • “Pioneering gene therapies for CNS disorders”
• Adrien Lemoine, VP Business Development & Operations, Orchard Therapeutics
  • “Overcoming the complex challenges associated with the development of ex vivo gene therapies for rare diseases”
• Karen Hodgkin, Chief Operating Officer, Cell Medica
  • “Cell Medica: Novel approaches for the treatment of Solid Tumours”
• James McBlane, CAT Alternate Member, Preclinical Assessor, UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • “Partnering well together – creating a global ecosystem for advanced therapies”
• Gabriele Proetzel, Director, Regenerative Medicine, Takeda (moderator)

R&D and Commercialisation 2020 – Maximising the Value of European Innovation

Key Topics:
– What is the UK doing to foster and support both the ATMP (regenerative medicine) sector, and improve the landscape broadly for European innovation?
– How can the EU create value from ‘home grown’ ATMPs while they continue to seek international partnerships? Is manufacturing a key to keeping more of the value chain in the EU?
– How are each of your organisations addressing the changing EU environment for ATMPs? How specifically are you adapting to meet the needs of the coming 3 – 5 years in technology developments in regenerative medicines?

• Magda Papadaki, Head of Product and Process Innovation, Association of the British Pharmaceutical Industry (ABPI)
• Barbara Freischem, Executive Director, European Biopharmaceutical Enterprises (EBE)
• Deborah Morrison, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE)
• Steve Bates, Chief Executive Officer, BioIndustry Association (BIA)
• Michael Stein, Chief Executive Officer and Chairman, Oxstem Ltd
• Duane Schulthess, Managing Director, Vital Transformation (moderator)